Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Haemolytic-uraemic syndrome: basic science

J L Moake1

  • 1Baylor College of Medicine, Methodist Hospital, Houston, Texas 77030.

Lancet (London, England)
|February 12, 1994
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disulfide bond reduction of von Willebrand factor by ADAMTS-13.

Journal of thrombosis and haemostasis : JTH·2010
Same author

Protein phosphatase 2B inhibition promotes the secretion of von Willebrand factor from endothelial cells.

Journal of thrombosis and haemostasis : JTH·2009
Same author

Covalent regulation of ULVWF string formation and elongation on endothelial cells under flow conditions.

Journal of thrombosis and haemostasis : JTH·2008
Same author

Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura.

Journal of thrombosis and haemostasis : JTH·2006
Same author

Platelet-derived VWF-cleaving metalloprotease ADAMTS-13.

Journal of thrombosis and haemostasis : JTH·2005
Same author

Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress.

Journal of thrombosis and haemostasis : JTH·2005
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles